Federation Des Caisses Desjardins Du Quebec Syndax Pharmaceuticals Inc Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 30, 2024	SELL	$8.94 - $20.98 $2,235 - $5,245	-250 Closed	0 $0
Q4 2018 Aug 30, 2024	BUY	$3.6 - $8.42 $900 - $2,105	250 New	250 $1.11 Million
Q4 2017 Aug 30, 2024	BUY	$7.8 - $12.94 $1,950 - $3,235	250	250 $2.19 Million

Others Institutions Holding SNDX

# of Institutions

228

Shares Held

88.4M

Call Options Held

1.01M

Put Options Held

692K

Black Rock Inc. New York, NY

7.91M
Shares

$118 Million
0.0% of portfolio
Kynam Capital Management, LP Princeton, NJ

5.84M
Shares

$87.3 Million
9.23% of portfolio
Wellington Management Group LLP Boston, MA

4.99M
Shares

$74.5 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

4.89M
Shares

$73 Million
0.0% of portfolio
Eversept Partners, LP New York, NY

4.11M
Shares

$61.3 Million
6.25% of portfolio

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $845M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account